Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

How Much Delay In Alzheimer’s Disease Progression Is Clinically Meaningful?

13 Jun 2023

• By Brenda Sandburg

Alzheimer's disease progression — Some question whether delay in cognitive decline in those receiving Alzheimer's drug Leqembi is clinically meaningful • Source: Shutterstock

Related Content

Eisai Pricing For Lecanemab Reflects Concern With Medicare ‘Sustainability,’ ‘Giving Back,’ Firm Says

07 Jan 2023

Sarepta’s DMD Gene Therapy: FDA Says Concluding Effectiveness Or Ineffectiveness Is ‘Challenging’

11 May 2023

Sarepta’s DMD Gene Therapy: Approval Delayed And Indication Narrowed, But Still On Track

25 May 2023

Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year

06 Jan 2023

Eisai/Biogen’s Leqembi Breezes Through Adcomm, Labeling Discussions With US FDA May Be Knottier

10 Jun 2023

US FDA Sees Leqembi Data As Vindicating Its Approach To Alzheimer’s Drugs

11 Jun 2023

Eisai/Biogen’s Leqembi Sees Clear Path To Regular Approval For Alzheimer’s Disease

08 Jun 2023

Related Companies

Eisai Co., Ltd.

Biogen, Inc.

Sarepta Therapeutics, Inc.

Additional Topics

United States Advisory Committees Drug Approval Standards Drug Review Review Pathway Clinical Trials Biologics Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.